New Survey Shows Majority Of Doctors In Favor Of National Marijuana Legalization
April 2nd, 2014
According to a new survey from WebMD, a majority of doctors nationwide support the national legalization of medical marijuana. WebMD, which is a highly regarded, award-winning provider of information/tools to manage health, surveyed 1,533 doctors from 48 states.
The results of the survey are as follows:
- 69 percent say it can help with certain treatments and conditions.
- 67 percent say it should be a medical option for patients.
- 56 percent support making it legal nationwide.
- 50 percent of doctors in states where it is not legal say it should be legal in their states.
- 52 percent of doctors in states considering new laws say it should be legal in their states.
In addition to these statistics, 82 percent of oncologists and hematologists called for medical marijuana, saying that the drug has delivered real benefits for patients.
The report recognized that medical research has been limited due to the federal government’s view of marijuana as a “Schedule I” substance, which places marijuana among the most dangerous drugs. According to the feds, Schedule I drugs have ““no accepted medicinal use” and have high potential for abuse.
WebMD Chief Medical Editor, Dr. Michael W. Smith, stated that even though the medical community may not be aware of long term effects due to lack of research opportunities, doctors still “support using marijuana as a potential treatment option for any number of medical problems,” adding that “many doctors already prescribe it” in the 20 states (plus the District of Columbia) where medical marijuana is legal.
The results of this survey expand the argument for the rescheduling of marijuana. Though the American Medical Association has not come out for or against medical marijuana, they have called for the federal government to review their classification of the drug, and urged research grants to be issued for the clinical research of cannabis.
420 Investor Alan Brochstein told Benzinga that he views these survey results as “huge news” for the cannabis sector, noting that broad support from doctors might help to advance the case for marijuana’s rescheduling, opening the door for future medical studies. “As more research emerges, potential benefits and risks will become more clear,” which would bring more certainty to the industry.
Just last month, for the first time ever, the Feds approved a medical marijuana study at the University of Arizona. This signaled a major shift in medical marijuana development research.
Due to the increasing support for medical (and recreational) legalization, WebMD has launched the Marijuana on Main Street Special Report, which is designed to help patients/recreational cannabis users recognize the potential health benefits and side effects of marijuana.
Read more: http://www.benzinga.com/news/14/04/4440847/new-survey-shows-majority-of-doctors-in-favor-of-national-marijuana-legalization#ixzz2xksJ0m5Q
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.